Tag Archive for: AMSilk

AMSilk’s bioengineered silk protein yarns debut in Balenciaga Spring 2026 Collection

/in

First commercially available products using AMSilk’s biotech silk protein yarns Demonstrating a scalable, low impact alternative to conventional silk within luxury fashion Designed for resilient, transparent and regionally integrated supply chains Neuried, Germany, January 21, 2026 – AMSilk GmbH (“AMSilk”), a global leader in advanced biomaterials made from silk proteins, today announced that its bioengineered […]

Read more

Evonik and AMSilk extend partnership for sustainable biotech silk materials

/in

Dedicated manufacturing line for AMSilk high-performance silk proteins High tech industrial biomaterials meet leading apparel brands’ demand for scalable, sustainable, alternatives Expanding Evonik’s portfolio of precision biosolutions ESSEN, Germany and NEURIED, Germany, Sept. 25, 2025 –  Evonik and AMSilk, a global leader in advanced biomaterials based on silk proteins, have deepened their collaboration with a long-term agreement to produce […]

Read more

Weekly roundup: An A* week! Advancements, acquisitions, appointments and Series A financings!

/in ,

AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth AMSilk GmbH has successfully secured EUR 52 million financing led by existing investor ATHOS (AT Newtec), along with strong participation from fellow existing investors MIG Capital and Novo Holdings. The financing will enable AMSilk to scale industrial production and meet global customer demand for its […]

Read more

AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth

/in

Funding enables AMSilk to scale industrial production and meet global customer demand for biotech produced silk-based protein materials The financing round was led by existing investor ATHOS (AT Newtec), with strong participation from fellow existing investors MIG Capital and Novo Holdings The total EUR 52M includes EUR 30M in cash and EUR 22M in convertible […]

Read more

Weekly roundup: Innovation and deals for Optimum’s clients

/in

SpliceBio secures $135 Million Series B financing to advance lead program SB-007 in Stargardt disease and expand pipeline of genetic medicines SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi […]

Read more